EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis

被引：1
|
作者：
Jiang, L. -J. [1 ]
Chau, M. [1 ]
Li, Y. [1 ]
Briand, F. [2 ]
Sulpice, T. [2 ]
Or, Y. S. [1 ]
机构：
[1] Enanta Pharmaceut Inc, Watertown, MA USA
[2] Physiogenex, Labege, France
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)31237-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-363
引用
收藏
页码：S434 / S434
页数：1
相关论文
共 50 条
  • [1] A HIGHLY SELECTIVE AND POTENT FARNESOID X RECEPTOR (FXR) AGONIST EDP-305 REDUCES LIVER STEATOSIS, BALLOONING, AND NON-ALCOHOLIC FATTY LIVER DISEASE ACTIVITY (NAS) IN TWO MURINE MODELS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    Jiang, Li-Juan
    Chau, Mary
    Li, Yang
    Or, Yat Sun
    GASTROENTEROLOGY, 2018, 154 (06) : S1159 - S1159
  • [2] A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis
    Klucher, Kevin
    Wang, Yujin
    Halcomb, Randall
    Fenaux, Martijn
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E534 - E534
  • [3] miR-101 IN STEATOSIS AND STEATOHEPATITIS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Elfimova, N.
    Ommer, K.
    Schlattjan, M.
    Sowa, J. P.
    Wedemeyer, I.
    Vantler, M.
    Dienes, H. P.
    Canbay, A.
    Odenthal, M.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S508 - S508
  • [4] A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Otgonsuren, Munkhzul
    Estep, Michael J.
    Hossain, Nayeem
    Younossi, Elena
    Frost, Spencer
    Henry, Linda
    Hunt, Sharon
    Fang, Yun
    Goodman, Zachary
    Younossi, Zobair M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (12) : 2006 - 2013
  • [5] Nicht alkoholische Fettleberkrankheit (NAFLK) Steatosis hepatis — NASH Non-alcoholic fatty liver disease (NAFLD) Non-alcoholic steatohepatitis − NASH
    K.-M. Keller
    Monatsschrift Kinderheilkunde, 2004, 152 : 864 - 869
  • [6] Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease
    Xu, Jiao-Ya
    Li, Zhong-Ping
    Zhang, Li
    Ji, Guang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (37) : 13493 - 13500
  • [7] Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease
    Jiao-Ya Xu
    Zhong-Ping Li
    Li Zhang
    Guang Ji
    World Journal of Gastroenterology, 2014, (37) : 13493 - 13500
  • [8] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, S.
    Trembling, P.
    Guha, I. N.
    Parkes, J.
    Kaye, P.
    Burt, A. D.
    Ryder, S. D.
    Aithal, G. P.
    Day, C. P.
    Rosenberg, W. M.
    GUT, 2011, 60 : A4 - A5
  • [9] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, Sudeep
    Trembling, Paul M.
    Guha, Indra Neil
    Parkes, Julie
    Kaye, Philip
    Burt, Alastair D.
    Ryder, Stephen D.
    Aithal, Guruprasad P.
    Day, Christopher P.
    Rosenberg, William M.
    HEPATOLOGY, 2011, 54 : 1123A - 1123A
  • [10] Agai improves non-alcoholic fatty liver disease (NAFLD) induced by fructose
    de Freitas Carvalho, Mayara Medeiros
    Teixeira Reis, Larissa Lelis
    Macedo Lopes, Juliana Marcia
    Lage, Nara Nunes
    da Costa Guerra, Joyce Ferreira
    Zago, Helena Porto
    Bonomo, Larissa de Freitas
    Pereira, Renata Rebeca
    de Lima, Wanderson Geraldo
    Silva, Marcelo Eustaquio
    Pedrosa, Maria Lucia
    NUTRICION HOSPITALARIA, 2018, 35 (02) : 318 - 325
12345